C-106 by Vicore Pharma for Idiopathic Pulmonary Fibrosis: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

C-106 overview

C-106 is under development for the treatment of idiopathic pulmonary fibrosis and pulmonary hypertension. The drug candidate is an oral small molecule which acts by targeting angiotensin II type 2 receptor (AT2R).

Vicore Pharma overview

Vicore Pharma formerly Pharmacore, a subsidiary of Vicore Pharma Holding AB, operates as a biotechnology company focused on the development of orphan drugs for the treatment of fibrotic diseases. Its lead product candidate C21 that stimulates the AT2 receptors is used for the treatment of idiopathic pulmonary fibrosis (IPF). Its portfolio includes small molecules with potential indications which are used in various therapeutic indications such as anti-inflammation, neuro protection, neuro regeneration, and cardiovascular diseases. The company seeks to work in collaboration with pharmaceutical companies to accelerate the development and licensing opportunities for its pipeline products. Vicore Pharma is headquartered in Molndal, Sweden.

For a complete picture of C-106’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.